Crispr Therapeutics Ag Stock Investor Sentiment
| CRSP Stock | USD 56.68 1.41 2.43% |
Slightly above 63% of Crispr Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Crispr Therapeutics AG suggests that many traders are alarmed. Crispr Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Crispr Therapeutics AG. Many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 37
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Crispr Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Crispr Therapeutics AG.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Crispr Historical Sentiment
Although Crispr Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Crispr, such as negative comments on social media and news outlets, may cause fear in the market and push Crispr Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Crispr.
Crispr Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Crispr Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Crispr Therapeutics Historical Investor Sentiment
Investor biases related to Crispr Therapeutics' public news can be used to forecast risks associated with an investment in Crispr. The trend in average sentiment can be used to explain how an investor holding Crispr can time the market purely based on public headlines and social activities around Crispr Therapeutics AG. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Crispr Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Crispr Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Crispr Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Crispr Therapeutics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Crispr Therapeutics' Stock prices. Below is the latest headlines and news related to Crispr Therapeutics Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Crispr Therapeutics that are available to investors today. This information is accessible both publicly - through Crispr Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Crispr-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Crispr Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Crispr Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Crispr Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Crispr Therapeutics alpha.
Crispr Largest EPS Surprises
Earnings surprises can significantly impact Crispr Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-11 | 2017-03-31 | -0.61 | -0.54 | 0.07 | 11 | ||
2019-07-29 | 2019-06-30 | -0.9 | -1.01 | -0.11 | 12 | ||
2025-11-05 | 2025-09-30 | -1.31 | -1.17 | 0.14 | 10 | ||
2020-10-28 | 2020-09-30 | -1.18 | -1.32 | -0.14 | 11 | ||
2019-02-25 | 2018-12-31 | -0.78 | -0.92 | -0.14 | 17 | ||
2018-08-07 | 2018-06-30 | -0.63 | -0.82 | -0.19 | 30 |
There is far too much social signal, news, headlines, and media speculation about Crispr Therapeutics that are available to investors today. This information is accessible both publicly - through Crispr Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Crispr-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Crispr Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Crispr Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Crispr Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Crispr Therapeutics alpha.
Crispr Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Can CRISPR Therapeutics In Vivo Breakthrough Reshape Its Long-Term Cardiovascular Ambitions | 11/11/2025 |
2 | Fanconi Anemia Market Research Report 2025-2035 Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based... | 11/18/2025 |
3 | Oppenheimer Reaffirms Outlook on CRISPR Therapeutics After Encouraging Q3 Earnings Performance | 11/25/2025 |
4 | What CRISPR Therapeutics Latest Trial Results Mean for Investors | 12/01/2025 |
5 | CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment | 12/02/2025 |
6 | uniQureN.V. A BearCase Theory | 12/04/2025 |
7 | Jump Financial LLC Buys New Shares in CRISPR Therapeutics AG CRSP | 12/08/2025 |
8 | Plant Breeding and CRISPR Plants Market Intelligence 2025-2030 Featuring Strategic Analysis of Advanta Seeds, Bayer, Dow, Eurofins, KWS and More | 12/09/2025 |
9 | Why Is CRISPR Therapeutics Up 3.3 percent Since Last Earnings Report | 12/10/2025 |
10 | A better DNA material for genetic medicine | 12/12/2025 |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.